Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient A case report

被引：0

作者：

Keiko Tanaka

Tatsuo Akechi

Mitsuo Yamazaki

Ryuichi Hayashi

Yutaka Nishiwaki

Yosuke Uchitomi

机构：

[1] Psychiatry Division,

[2] National Cancer Center Hospital East,undefined

[3] Kashiwanoha 6–5–1,undefined

[4] Kashiwa,undefined

[5] Chiba 277–8577,undefined

[6] Japan,undefined

[7] Department of Thoracic Oncology,undefined

[8] National Cancer Center Hospital East,undefined

[9] Kashiwanoha 6–5–1,undefined

[10] Kashiwa,undefined

[11] Chiba 277–8577,undefined

[12] Japan,undefined

[13] Psycho-Oncology Division,undefined

[14] National Cancer Center Research Institute East,undefined

[15] Kashiwanoha 6–5–1,undefined

[16] Kashiwa,undefined

[17] Chiba 277–8577,undefined

[18] Japan Tel.: +81–471–34–7013 Fax: +81–471–34–7026 email: yuchitom@east.ncc.go.jp,undefined

[19] Department of Head and Neck Surgery,undefined

[20] National Cancer Center Hospital East,undefined

[21] Kashiwanoha 6–5–1,undefined

[22] Kashiwa,undefined

[23] Chiba 277–8577,undefined

[24] Japan,undefined

来源：

Supportive Care in Cancer | 1998年 / 6卷

关键词：

Key words Neuroleptic malignant syndrome; Neuroleptics; Delirium; Cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A case of neuroleptic malignant syndrome (NMS) in a 64-year-old man with cancer of the soft palate is reported. During haloperidol treatment for delirium, the patient showed consciousness disturbance with extrapyramidal signs. With discontinuation of haloperidol and replacement by dantrolene and bromocriptine, the patient recovered completely. Although major tranquilizers are widely used in clinical oncology to manage symptoms, NMS has been rarely reported in cancer patients, presumably because of lack of awareness. Early recognition of NMS and prompt treatment may improve the potentially fatal outcome.

引用

页码：536 / 538

页数：2